Many Insys Therapeutics, Inc.(INSY) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Insys Therapeutics Inc was Reiterated by RBC Capital Mkts on Dec 21, 2016 to Outperform, Lowers Price Target to $ 16 from a previous price target of $23 .
Company has reported several Insider transactions to the SEC, on Nov 7, 2016, Steven J Meyer (director) purchased 10,000 shares at 10.75 per share price.On Aug 16, 2016, Theodore H Stanley (director) sold 15,000 shares at 18.02 per share price.On Aug 12, 2016, Patrick Fourteau (director) sold 15,000 shares at 18.46 per share price.
Insys Therapeutics Inc Last issued its quarterly earnings results on Nov 3, 2016. The company reported $0.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.02. Analyst had a consensus of $0.05. The company had revenue of $55.18 million for the quarter, compared to analysts expectations of $54.17 million. The companys revenue was down -39.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.50 EPS.
Insys Therapeutics, Inc. (NASDAQ:INSY) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 1.6 by 5 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 1 Brokerage Firms have advised hold.
Insys Therapeutics, Inc. (NASDAQ:INSY) should head towards $17.75 per share according to 4 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $16 per share. The higher price estimate target is at $20 according to the Analysts.
Insys Therapeutics, Inc. (NASDAQ:INSY) rose 1.47% or 0.14 points on Tuesday and made its way into the gainers of the day. After trading began at $9.4 the stock was seen hitting $9.77 as a peak level and $9.3 as the lowest level. The stock ended up at $9.64. The daily volume was measured at 1,153,075 shares. The 52-week high of the share price is $21.22 and the 52-week low is $8.7. The company has a market cap of $692 million.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The companys cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.